United Therapeutics price target raised to $525 from $405 at Cantor Fitzgerald

Cantor Fitzgerald analyst Olivia Brayer raised the firm’s price target on United Therapeutics (UTHR) to $525 from $405 and keeps an Overweight rating on the shares. The firm likes the setup on the stock because idiopathic pulmonary fibrosis is now largely de-risked, the analyst tells investors in a research note. Cantor believes the stock should trade “with a 5-handle,” and that “it’s only a matter of months” before it does.